Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 4Leukemia 4Hyperuricemia 4Leukemia, Myeloid, Acute 3Tumor Lysis Syndrome 2Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nutritional and Metabolic Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × rasburicase × Clear all
NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

M.D. Anderson Cancer Center

Phase 2 Completed
55 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡